5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
Marc Schneidman’s Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010.
Established in the year 2010, Aquilo Capital Management stands as a hedge fund manager with its headquarters situated in the vibrant city of San Francisco, California.
Marc Schneidman holds the position of Portfolio Manager at Aquilo Capital Management, bringing over two decades of expertise in biotechnology research and investing. Before joining Aquilo Capital, Marc was an integral part of the three-person portfolio management team at the Biotechnology Value Fund from 1995 to 2009. He has also contributed to various private biotechnology companies by serving on their Board of Directors. A graduate of the University of California, Santa Barbara, Marc holds a B.A. in Biological Sciences and earned a J.D. from Santa Clara University. Prior to his role at Aquilo Capital, Marc spent 14 years as a portfolio manager at BVF Partners L.P. (BVF), a dedicated life science investment fund. In this capacity, he was responsible for investment selection, research analysis, and portfolio management. Throughout his career, Marc has collaborated closely with portfolio companies on strategic development, corporate partnering, and structured financings, further enhancing his extensive industry experience. Marc's commitment to the life science sector is evident not only through his professional roles but also by serving on the board of several private life science companies. His educational background and wealth of experience uniquely position him as a seasoned professional in the field of biotechnology.
Aquilo Capital Management manages discretionary assets totaling $442.5 million according to the Form ADV filed on March 2023. Their most recent 13F filing for Q3 2023 disclosed $110.3 million in managed 13F securities, revealing a top 10 holdings concentration of 98.11%.
